Understanding COPD Phenotypes and Treatable Traits
A Study on COPD Phenotypes, Endotypes and Treatable Traits
This study is trying to find out different types of COPD and specific traits in patients that can be treated to help improve their health and management of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 460 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Drugs / interventions | Dupilumab |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT06952881 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the various phenotypes and endotypes of Chronic Obstructive Pulmonary Disease (COPD) and identify treatable traits that can improve patient outcomes. It will involve assessing patients with COPD based on their symptoms, lung function, and other characteristics to better understand the disease's heterogeneity. The research will focus on the unique aspects of COPD in the Hong Kong population, which may differ from findings in other regions. By identifying these traits, the study seeks to enhance management strategies for COPD patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 40 years and older who have been diagnosed with COPD and meet specific lung function criteria.
Not a fit: Patients with serious comorbidities that prevent them from participating in follow-up care may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with COPD.
How similar studies have performed: Previous studies have shown success in identifying specific endotypes and phenotypes in COPD, but this study aims to provide a more comprehensive understanding within the unique context of Hong Kong.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\) Patient with COPD with compatible history and lung function assessment according to Global Obstructive Lung Disease (GOLD): Patient has chronic respiratory symptoms (dyspnoea, cough, sputum production and exacerbations due to abnormalities of the airway (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow limitation. Lung function assessment with forced spirometry demonstrated the presence of a post-bronchodilator FEV1/FVC \<70%.14 2) Patient with age ≥40 years Exclusion Criteria: 1. Serious disease that would hinder the patient from having follow-up for 3 years, e.g. late-stage malignancy, severe heart failure and severe renal failure not on dialysis. 2. Unable to provide written informed consent.
Where this trial is running
Hong Kong
- The Chinese University of Hong Kong — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Fanny WS Ko, MD
- Email: fannyko@cuhk.edu.hk
- Phone: 852 35033133
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.